Bristol-Myers Squibb (BMY) Following Camzyos Data And Zola Cel Pause Still Looks Fully Valued

Bristol-Myers Squibb (BMY) is in focus after two contrasting clinical updates. Fresh five year data on Camzyos in obstructive hypertrophic cardiomyopathy landed alongside a voluntary enrollment pause in zola-cel autoimmune trials.

For context, Bristol-Myers Squibb’s share price has climbed 16.68% over the past 90 days and 24.99% year to date, while the 1 year total shareholder return of 48.55% points to momentum that has been building through recent clinical data, guidance updates, and the zola cel trial pause headlines.

Spot patterns in how Bristol-Myers Squibb handles risk and reward by comparing it with a curated shortlist of 82 resilient stocks with low risk scores.

After a 25% year to date climb, Bristol-Myers Squibb trades close to the average analyst target yet still screens at a sizeable intrinsic value discount. Is the market being prudently wary after the zola cel pause, or too cautious on the core business and Camzyos data?

Most Popular Narrative: 1% Overvalued

The most followed narrative places Bristol-Myers Squibb’s fair value at $66.21, slightly below the last close of $66.82. This implies a small valuation premium built on specific long term assumptions.

Analysts are assuming Bristol-Myers Squibb's revenue will decrease by 6.6% annually over the next 3 years.

Analysts assume that profit margins will increase from 18.9% today to 20.6% in 3 years time.

Read the complete narrative. Read the complete narrative.

Want to see how a shrinking top line, rising margins and a higher future earnings multiple still support a fair value close to today’s price? The most popular Bristol-Myers Squibb narrative leans on a detailed path for earnings, valuation multiples and discount rates, not just headline drug news or M&A chatter.

Result: Fair Value of $66.21 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Bristol-Myers Squibb still faces two clear swing factors: sizable patent cliffs on key drugs and evolving U.S. pricing rules that could pressure future margins.

Find out about the key risks to this Bristol-Myers Squibb narrative.

Another View on Bristol-Myers Squibb’s Valuation

Our DCF model presents a different perspective on Bristol-Myers Squibb. Using this approach, the fair value sits at $118.83 per share, compared with the current $66.82 price. That 43.8% discount indicates a sizeable gap. Is the market overreacting to the revenue decline forecasts?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

With Bristol-Myers Squibb generating differing opinions on risks and rewards, now may be a good time to review the numbers yourself and decide where you stand so you can weigh the 4 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Bristol-Myers Squibb?

If Bristol-Myers Squibb has sharpened your focus, now is a good moment to widen your watchlist and pressure test your thinking against other high quality opportunities.

• Start building a watchlist of potential bargains by scanning our 47 high quality undervalued stocks that combine quality fundamentals with discounted prices.
• Boost your income options by reviewing our 11 dividend fortresses that focus on higher yielding companies with an emphasis on resilience.
• Protect your downside by filtering for financially robust businesses using the list of solid balance sheet and fundamentals (52 results) so you are not caught off guard by weak balance sheets.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com